ATE430161T1 - Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung - Google Patents
Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendungInfo
- Publication number
- ATE430161T1 ATE430161T1 AT01980380T AT01980380T ATE430161T1 AT E430161 T1 ATE430161 T1 AT E430161T1 AT 01980380 T AT01980380 T AT 01980380T AT 01980380 T AT01980380 T AT 01980380T AT E430161 T1 ATE430161 T1 AT E430161T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- hsp70
- stimulates
- present
- cell activity
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 210000000822 natural killer cell Anatomy 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 title 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 title 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 230000004927 fusion Effects 0.000 abstract 2
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/07—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00119933 | 2000-09-13 | ||
| PCT/EP2001/010593 WO2002022656A2 (en) | 2000-09-13 | 2001-09-13 | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
| BE2009/0695A BE1019732A4 (fr) | 2000-09-13 | 2009-11-12 | Peptide de hsp70 simulant l'activite de cellules tueuses naturelles (nk) et ses utilisations. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE430161T1 true ATE430161T1 (de) | 2009-05-15 |
Family
ID=47436345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01980380T ATE430161T1 (de) | 2000-09-13 | 2001-09-13 | Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7517948B2 (de) |
| EP (1) | EP1319023B8 (de) |
| AT (1) | ATE430161T1 (de) |
| AU (1) | AU2002212236A1 (de) |
| BE (1) | BE1019732A4 (de) |
| DE (1) | DE60138558D1 (de) |
| ES (1) | ES2326114T3 (de) |
| WO (1) | WO2002022656A2 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1319023B8 (de) * | 2000-09-13 | 2009-07-15 | multimmune GmbH | Peptid aus hsp70 welches nk zellaktivität stimuliert und seine verwendung |
| IL148401A0 (en) * | 2002-02-26 | 2002-09-12 | Hadasit Med Res Service | Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases |
| DK1537204T3 (da) * | 2002-08-23 | 2010-06-07 | Gabriele Prof Dr Multhoff | Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller |
| US7943740B2 (en) * | 2003-12-05 | 2011-05-17 | Multimmune Gmbh | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases |
| DE602004020266D1 (de) * | 2003-12-05 | 2009-05-07 | Multimmune Gmbh | Therapeutische und diagnostische anti-hsp 70-antikörper |
| CA2702370A1 (en) * | 2006-11-14 | 2008-05-22 | Ralf Dressel | Compositions and methods for immunotherapy |
| GB0705626D0 (en) * | 2007-03-23 | 2007-05-02 | Royal Veterinary College | Method for enhancing sperm survival |
| AU2009262670B2 (en) | 2008-06-26 | 2013-06-20 | Zevra Denmark A/S | Use of Hsp70 as a regulator of enzymatic activity |
| WO2012023631A1 (ja) * | 2010-08-19 | 2012-02-23 | 株式会社Eci | ヒートショックプロテイン（ｈｓｐ）とｅｃｉ３０１ポリペプチドを含む癌細胞の増殖を抑制するための医薬組成物ならびにそれを用いた癌の治療方法 |
| PL2646044T3 (pl) | 2010-11-30 | 2020-03-31 | Orphazyme A/S | Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70 |
| US20160000777A1 (en) * | 2013-02-21 | 2016-01-07 | University Of Rochester | Methods of using histamine receptor agonists and antagonists |
| EP3193840B1 (de) | 2014-09-15 | 2021-05-19 | Orphazyme A/S | Arimoclomolformulierung |
| EP3925968A3 (de) | 2014-10-07 | 2022-03-02 | Cytlimic Inc. | Aus hsp70 gewonnenes peptid, pharmazeutische zusammensetzung zur behandlung oder vorbeugung von krebs unter verwendung davon, immunitätsinduzierer und verfahren zur herstellung von antigen-präsentierender zelle |
| CA2973524A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy |
| CA2981468A1 (en) | 2015-04-07 | 2016-10-13 | Cytlimic Inc. | Medicine |
| CN109562154A (zh) * | 2016-03-10 | 2019-04-02 | 爱普瑞希斯有限公司 | 带有修饰hsp70域的抗原结合融合蛋白 |
| WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
| US20190111041A1 (en) | 2016-04-29 | 2019-04-18 | Orphazyme A/S | Arimoclomol for treating glucocerebrosidase associated disorders |
| JP2019528071A (ja) * | 2016-08-23 | 2019-10-10 | エイムヴィオン・アクティエセルスカブＡｉｍＶｉｏｎ Ａ／Ｓ | 新規免疫刺激ペプチド |
| CN106317216B (zh) * | 2016-09-21 | 2019-07-19 | 南京农业大学 | 一种促进h9n2禽流感疫苗免疫效果的活性肽及应用 |
| US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
| CA3071217A1 (en) * | 2017-08-31 | 2019-03-07 | Multimmune Gmbh | Hsp70 based combination therapy |
| US20230416224A1 (en) | 2020-11-19 | 2023-12-28 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268478B1 (en) * | 1996-02-12 | 2001-07-31 | Cedars-Sinai Medical Center | Intracellular vitamin D binding protein |
| EP1066050B2 (de) * | 1998-03-27 | 2010-06-02 | Gabriele Prof. Dr. Multhoff | Verwendung von hsp70 protein |
| CN1057363C (zh) | 1998-07-10 | 2000-10-11 | 贺德新 | 一种液压挤扩装置 |
| AU760081B2 (en) * | 1998-11-24 | 2003-05-08 | Bristol-Myers Squibb Company | Intracellular targeted delivery of compounds by 70 kD heat shock protein |
| EP1319023B8 (de) * | 2000-09-13 | 2009-07-15 | multimmune GmbH | Peptid aus hsp70 welches nk zellaktivität stimuliert und seine verwendung |
-
2001
- 2001-09-13 EP EP01980380A patent/EP1319023B8/de not_active Expired - Lifetime
- 2001-09-13 AT AT01980380T patent/ATE430161T1/de active
- 2001-09-13 ES ES01980380T patent/ES2326114T3/es not_active Expired - Lifetime
- 2001-09-13 WO PCT/EP2001/010593 patent/WO2002022656A2/en active Application Filing
- 2001-09-13 US US10/380,408 patent/US7517948B2/en not_active Expired - Lifetime
- 2001-09-13 DE DE60138558T patent/DE60138558D1/de not_active Expired - Lifetime
- 2001-09-13 AU AU2002212236A patent/AU2002212236A1/en not_active Abandoned
-
2009
- 2009-03-02 US US12/395,818 patent/US7745399B2/en not_active Expired - Fee Related
- 2009-11-12 BE BE2009/0695A patent/BE1019732A4/fr active
Also Published As
| Publication number | Publication date |
|---|---|
| US7517948B2 (en) | 2009-04-14 |
| WO2002022656A2 (en) | 2002-03-21 |
| EP1319023A2 (de) | 2003-06-18 |
| BE1019732A4 (fr) | 2012-12-04 |
| DE60138558D1 (de) | 2009-06-10 |
| AU2002212236A1 (en) | 2002-03-26 |
| WO2002022656A3 (en) | 2002-09-26 |
| US7745399B2 (en) | 2010-06-29 |
| US20090239802A1 (en) | 2009-09-24 |
| ES2326114T3 (es) | 2009-10-01 |
| EP1319023B1 (de) | 2009-04-29 |
| US20040063173A1 (en) | 2004-04-01 |
| EP1319023B8 (de) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE430161T1 (de) | Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung | |
| DE69435075D1 (de) | , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten | |
| DE50004018D1 (de) | Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen | |
| EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| EA200200755A1 (ru) | Опосредованная рецептором nogo блокада роста аксонов | |
| EP2014678A3 (de) | KDR-Peptide und Impfstoffe damit | |
| WO2002044320A3 (en) | Human elongase genes and uses thereof | |
| EP1289551A4 (de) | HUMANE POLYPEPTIDE WELCHE ZUM ABSTERBEN VON ZELLEN, INSBESONDERE LYMPHOIDER TUMORZELLEN, FüHREN | |
| DE602006020898D1 (de) | Peptide zur förderung des haarwachstums und zur verbesserung von falten und kosmetische zusammensetzungen, die diese enthalten | |
| NL300830I1 (nl) | Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten | |
| TW200407425A (en) | Human coagulation factor VII polypeptides | |
| IL173952A0 (en) | Anti-angiogenic peptides and pharmaceutical compositions based thereon | |
| EP1978994A4 (de) | Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen | |
| HUP0100267A2 (hu) | Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények | |
| ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| EP1613345A4 (de) | Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320 | |
| DE60118359D1 (de) | Humanische pellino-polypeptide | |
| DE69534633D1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| UA84831C2 (ru) | Производные фактора коагуляции vii | |
| TR199902866T2 (xx) | Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler. | |
| CY1109617T1 (el) | Ενα πεπτιδιο hsp70 που διεγειρει τη δραστηριοτητα φυσικων φονικων κυτταρων (νκ) και χρησεις αυτου | |
| ATE338063T1 (de) | Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers | |
| DK0811068T3 (da) | Humane DNase I varianter | |
| WO2003025014A3 (fr) | Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes | |
| ATE400288T1 (de) | Peptide mit hohem cysteingehalt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1319023 Country of ref document: EP |